XML 57 R62.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Summarized quarterly financial data for fiscal years 2019 and 2018 is as follows: (Details) - USD ($)
3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Revenues $ 15,902,000 $ 23,719,000 $ 6,079,000 $ 3,947,000 $ 5,089,000 $ 3,474,000 $ 3,763,000 $ 3,773,000 $ 49,646,937 $ 16,099,460 $ 16,777,713
Gross profit 13,023,000 22,275,000 4,830,000 3,184,000 4,139,000 2,775,000 3,309,000 3,139,000 43,312,352 13,361,808 14,140,770
Net loss $ (49,435,000) $ (31,967,000) $ (55,237,000) $ (39,506,000) $ (39,391,000) $ (35,605,000) $ (33,219,000) $ (24,402,000) $ (176,144,999) $ (132,617,160) $ (76,925,380)
Loss per common share, basic and diluted $ (0.19) $ (0.13) $ (0.23) $ (0.16) $ (0.17) $ (0.16) $ (0.15) $ (0.11) $ (0.72) $ (0.59) $ (0.37)
Loss on extinguishment of debt     $ 10,100,000           $ 10,057,632
License Agreement Theramex                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Revenues   $ 15,500,000